$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market ...

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and ...

Atai Life Sciences announced a financing deal to raise approximately $50 million by selling 18,264,840 ordinary shares and pre-funded warrants to purchase an additional 4,566,210 shares. The funds ...

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today ...

Private placement securities continue to offer insurers attractive opportunities to enhance portfolio income, according to a recent Conning report. Conning’s latest Viewpoint commentary, “Private ...

– Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis, and Transition into a Commercial ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction ...

Stephen Twomey has published an educational resource analyzing the risks associated with 506(b) private placement investments. The article, Risks of 506(b) Private Placements, outlines structural, ...

The landscape of retirement planning may soon change profoundly. With the recent signing of an executive order aimed at allowing 401(k) plans to include alternative investments such as private equity, ...

Stephen Twomey has released a new informative resource exploring how private placements function within a self-directed IRA, the rules governing their use, and the potential benefits accredited ...